ZVRA ZEVRA THERAPEUTICS, INC.
8-K Current Report
Filed: March 9, 2026
Health Care
Pharmaceutical PreparationsZEVRA THERAPEUTICS, INC. (ZVRA) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items2 items
- Item 2.02: Results of Operations and Financial Condition
- Item 5.02: Departure/Election of Directors or Officers
AI Filing Analysis8-K
Item 2.02 · Results of Operations and Financial Condition
- • Q4 2025 earnings release issued March 9, 2026 — full financial results and corporate updates in Exhibit 99.1
- • Conference call/webcast scheduled March 9, 2026 at 4:30 p.m. ET to discuss results
Item 5.02 · Departure/Election of Directors or Officers
- • Justin Renz appointed CFO effective March 9, 2026; seasoned biopharma CFO with prior roles at Ardelyx, Correvio, and Karyopharm
- • Base salary $520,000 with 45% annual bonus target (~$234,000 target bonus)
Other ZEVRA THERAPEUTICS, INC. 8-K Filings
Get deeper insights on ZEVRA THERAPEUTICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.